When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CRNX - Crinetics Pharma's paltusotine shows encouraging action in mid-stage study
Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals (NASDAQ:CRNX) reports positive interim data from a Phase 2 clinical trial, ACROBAT EDGE, evaluating oral paltusotine (CRN00808) in patients with acromegaly, a rare disorder in which the pituitary gland produces too much growth hormone which causes bones to increase in size, including the face, hands and feet.
More news on: Crinetics Pharmaceuticals, Inc., Healthcare stocks news,